Treatment of subretinal neovascular membrane in a patient with membranoproliferative glomerulonephritis type II.
A 29-year-old woman with membranoproliferative glomerulonephritis type II presented with decreased vision due to choroidal neovascular membrane. She was treated with monthly intravitreal injections of bevacizumab. Although there was dramatic improvement in her vision after the third injection, it continued to improve through the ninth monthly injection. Despite recent reports of renal side effects of systemic bevacizumab, patients with preexisting renal disease treated by the authors did not demonstrate any loss of renal function 1 year after treatment.